Morgan Stanley analyst John Glass maintains Krispy Kreme (NASDAQ:DNUT) with a Overweight and lowers the price target from $23 to $21.
Amgen’s Repatha Shows Long Term Lowering Of Bad Cholesterol, Tolerance
Amgen Inc (NASDAQ:AMGN) presented new data from the Phase 3 FOURIER open-label extension (OLE) studies of Repatha (evolocumab) in adults with…